Glazer Capital’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$23.6M Sell
2,343,278
-6,483
-0.3% -$65.1K 0.58% 27
2026
Q1
$23.4M Sell
2,349,761
-138
-0% -$1.38K 0.5% 30
2025
Q4
$23.3M Buy
+2,349,899
New +$23.2M 0.61% 29

Other funds holding DMII

Glazer Capital's DMII Position: Q2 2026 in Review

Glazer Capital reduced its Drugs Made In America Acquisition II Corp (DMII) stake by 0.28% in Q2 2026, selling an estimated $65.1K and leaving 2,343,278 shares worth $23.6M. The position accounts for 0.58% of the portfolio, ranked #27.

Glazer Capital first reported a position in DMII in Q4 2025 and has held it in 3 quarters since. 69 funds tracked by Wall St. Rank hold DMII as of Q2 2026.

  • Glazer Capital held 2,343,278 shares of Drugs Made In America Acquisition II Corp worth $23.6M as of Q2 2026.
  • Glazer Capital sold 6,483 Drugs Made In America Acquisition II Corp shares in Q2 2026, an estimated $65.1K.
  • Drugs Made In America Acquisition II Corp made up 0.58% of Glazer Capital's portfolio in Q2 2026, its #27 holding.
  • Glazer Capital first reported a position in Drugs Made In America Acquisition II Corp in Q4 2025 and has held it in 3 quarters since.
  • 69 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q2 2026.

Based on Glazer Capital's 13F filing for Q2 2026, filed 17 Aug 2026.